Skip to main content
Clinical Trials/NCT00998569
NCT00998569
Completed
Not Applicable

Neurocognitive Enhancement in Major Depressive Disorder

Queen's University1 site in 1 country33 target enrollmentOctober 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Queen's University
Enrollment
33
Locations
1
Primary Endpoint
Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to examine the effects of neurocognitive enhancement on cognitive abilities and related social and adaptive behaviours in individuals diagnosed with major depressive disorder. Subjects in this study will be randomized to receive Neurocognitive Enhancement Therapy (NET) or to a wait list and then NET . Secondary aims include examining whether the cognitive benefits are potentiated by repeated exposure during in-home practice with complementary exercises. Additionally, the investigators will examine the durability of the effects and their generalization to functional capacity and everyday functional performance after completion of the groups.

Registry
clinicaltrials.gov
Start Date
October 2009
End Date
March 2012
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christopher Bowie

Ph.D.

Queen's University

Eligibility Criteria

Inclusion Criteria

  • Male or Female.
  • Subjects will be between the ages of 18 and 65, which is the age range with available normative comparison data.

Exclusion Criteria

  • Presence of a medical diagnosis that is associated with known cognitive impairments, such as multiple sclerosis, cerebrovascular accident, dementia, or history of traumatic brain injury.
  • Subjects with a reading level below grade 6, as assessed with the Wide Range Achievement Test - Reading Recognition Subtest, will be excluded because of the likelihood of not understanding task instructions.
  • Subjects with uncorrectable vision or hearing impairment that would preclude valid assessments or intervention procedures.

Outcomes

Primary Outcomes

Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance

Time Frame: 20 weeks

Study Sites (1)

Loading locations...

Similar Trials